These modifications hint at weaknesses in the cancers growth systems that could be targeted by new, less harmful therapies.Challenges in Cancer GeneticsThe concept of establishing molecular profiles of tumors is not brand-new. “Compared with other cancers, finding Hodgkin lymphoma cancer cells or cancer DNA to research study is like browsing for a needle in a haystack.”Compared with other cancers, finding Hodgkin lymphoma cancer cells or cancer DNA to study is like browsing for a needle in a haystack,” Ash Alizadeh stated. Thats because, unlike lots of other cancers, Hodgkin lymphoma tumors are made up mainly of immune cells that have actually infiltrated the cancer, making it hard to isolate the unhealthy cells for study.”Reference: “Distinct Hodgkin lymphoma subtypes specified by noninvasive genomic profiling” by Stefan K. Alig, Mohammad Shahrokh Esfahani, Andrea Garofalo, Michael Yu Li, Cédric Rossi, Tim Flerlage, Jamie E. Flerlage, Ragini Adams, Michael S. Binkley, Navika Shukla, Michael C. Jin, Mari Olsen, Adèle Telenius, Jurik A. Mutter, Joseph G. Schroers-Martin, Brian J. Sworder, Shinya Rai, Daniel A. King, Andre Schultz, Jan Bögeholz, Shengqin Su, Karan R. Kathuria, Chih Long Liu, Xiaoman Kang, Maya J. Strohband, Deanna Langfitt, Kristine Faye Pobre-Piza, Sherri Surman, Feng Tian, Valeria Spina, Thomas Tousseyn, Lieselot Buedts, Richard Hoppe, Yasodha Natkunam, Luc-Matthieu Fornecker, Sharon M. Castellino, Ranjana Advani, Davide Rossi, Ryan Lynch, Hervé Ghesquières, Olivier Casasnovas, David M. Kurtz, Lianna J. Marks, Michael P. Link, Marc André, Peter Vandenberghe, Christian Steidl, Maximilian Diehn and Ash A. Alizadeh, 11 December 2023, Nature.DOI: 10.1038/ s41586-023-06903-xResearchers from British Columbia Cancer, University Hospital François Mitterand, St. Jude Childrens Research Hospital, the Oncology Institute of Southern Switzerland, KU Leuven, the University of Strasbourg, Emory University, the Fred Hutchinson Cancer Research Center, the Hospices Civils de Lyon, and the Université Catholique de Louvain contributed to the work.This work was supported by the National Institutes of Health (grants R01CA257655, R01CA233975, and R03CA21765), the Department of Defense, the Virginia and D.K. Ludwig Fund for Cancer Research, a Hanna and Michael Murphy household present, the Stanford Cancer Institute, the Damon Runyon Cancer Research Foundation, an American Society of Hematology Scholar Award, the V Foundation for Cancer Research, the Emerson Collective Cancer Research Fund, a Stinehart/Reed Award, the CRK Faculty Scholar Fund, the Lung Cancer Research Foundation and the SDW/DT, the Shanahan Family Foundations, the Terry Fox Research Institute, the Canadian Institutes of Health Research, an Elizabeth C. Watters Research Fellowship, and the American Syrian Lebanese Associated Charities.Diehn, Alizadeh, Alig and Esfahani have actually filed patents related to cancer biomarkers.
“Compared with other cancers, discovering Hodgkin lymphoma cancer cells or cancer DNA to study is like browsing for a needle in a haystack.”Compared with other cancers, finding Hodgkin lymphoma cancer cells or cancer DNA to research study is like browsing for a needle in a haystack,” Ash Alizadeh stated.”Reference: “Distinct Hodgkin lymphoma subtypes specified by noninvasive genomic profiling” by Stefan K. Alig, Mohammad Shahrokh Esfahani, Andrea Garofalo, Michael Yu Li, Cédric Rossi, Tim Flerlage, Jamie E. Flerlage, Ragini Adams, Michael S. Binkley, Navika Shukla, Michael C. Jin, Mari Olsen, Adèle Telenius, Jurik A. Mutter, Joseph G. Schroers-Martin, Brian J. Sworder, Shinya Rai, Daniel A. King, Andre Schultz, Jan Bögeholz, Shengqin Su, Karan R. Kathuria, Chih Long Liu, Xiaoman Kang, Maya J. Strohband, Deanna Langfitt, Kristine Faye Pobre-Piza, Sherri Surman, Feng Tian, Valeria Spina, Thomas Tousseyn, Lieselot Buedts, Richard Hoppe, Yasodha Natkunam, Luc-Matthieu Fornecker, Sharon M. Castellino, Ranjana Advani, Davide Rossi, Ryan Lynch, Hervé Ghesquières, Olivier Casasnovas, David M. Kurtz, Lianna J. Marks, Michael P. Link, Marc André, Peter Vandenberghe, Christian Steidl, Maximilian Diehn and Ash A. Alizadeh, 11 December 2023, Nature.DOI: 10.1038/ s41586-023-06903-xResearchers from British Columbia Cancer, University Hospital François Mitterand, St. Jude Childrens Research Hospital, the Oncology Institute of Southern Switzerland, KU Leuven, the University of Strasbourg, Emory University, the Fred Hutchinson Cancer Research Center, the Hospices Civils de Lyon, and the Université Catholique de Louvain contributed to the work.This work was supported by the National Institutes of Health (grants R01CA257655, R01CA233975, and R03CA21765), the Department of Defense, the Virginia and D.K. Ludwig Fund for Cancer Research, a Hanna and Michael Murphy household present, the Stanford Cancer Institute, the Damon Runyon Cancer Research Foundation, an American Society of Hematology Scholar Award, the V Foundation for Cancer Research, the Emerson Collective Cancer Research Fund, a Stinehart/Reed Award, the CRK Faculty Scholar Fund, the Lung Cancer Research Foundation and the SDW/DT, the Shanahan Family Foundations, the Terry Fox Research Institute, the Canadian Institutes of Health Research, an Elizabeth C. Watters Research Fellowship, and the American Syrian Lebanese Associated Charities.Diehn, Alizadeh, Alig and Esfahani have actually filed patents associated to cancer biomarkers.
